China Isotope & Radiation Corp
HKEX:1763
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (1.9), the stock would be worth HK$8.3 (56% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.2 | HK$18.66 |
0%
|
| 3-Year Average | 1.9 | HK$8.3 |
-56%
|
| 5-Year Average | 2.7 | HK$12.22 |
-35%
|
| Industry Average | 26.2 | HK$116.53 |
+524%
|
| Country Average | 28.8 | HK$128.17 |
+587%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
C
|
China Isotope & Radiation Corp
HKEX:1763
|
6B HKD | 4.2 | 15.9 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 28 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 14.4 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 12.5 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 14.3 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 11.5 | 32.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 16.8 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 23.8 | 50.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
36.7B CNY | 20.9 | 23.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -80.8 | -36.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
China Isotope & Radiation Corp
Glance View
China Isotope & Radiation Corp. engages in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications. The company is headquartered in Beijing, Beijing. The company went IPO on 2018-07-06. The firm also provides radiation sterilization services. The firm is also involved in the design, manufacture and installation of Gama ray irradiation devices. The firm opeartes its businesse mainly through four segments, including the Pharmaceuticals segment, the Radiological Products segment, the Irradiation segment and the Independent Medical Laboratory Services and Others segment, with the Pharmaceuticals segment as the core segment. The Pharmaceuticals segment is engaged in the development, manufacture and sale of radiopharmaceuticals, the Kit for Urea Breath Test and testing instruments, as well as in vitro immunodiagnostic reagents and boxes for imaging diagnosis and treatment.
